UK Markets open in 3 hrs 8 mins


Dusseldorf - Dusseldorf Delayed price. Currency in EUR
Add to watchlist
43.50-1.06 (-2.38%)
At close: 8:09AM CEST
Full screen
Previous close44.56
Bid0.00 x 0
Ask0.00 x 0
Day's range43.50 - 43.50
52-week range39.63 - 56.35
Avg. volume17
Market capN/A
PE ratio (TTM)N/A
Earnings dateN/A
Dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • days ago

    This small-cap growth stock could be a millionaire-maker

    Bilaal Mohamed believes this hidden gem could help you on the road to riches.

  • Market Realist5 days ago

    What’s Cooperman’s View on Shire?

    Shire was the seventh-largest holding in Cooperman's Omega Advisors’ portfolio in 2Q17, representing nearly 3.5% of total holdings.

  • Reuters - UK Focus9 days ago

    Shire says trial shows new HAE drug significantly reduces attacks

    London-listed drugmaker Shire (Hamburg: 3979575.HM - news) said on Monday it had successfully tested a new medicine that prevents attacks in patients with hereditary angioedema (HAE), a rare genetic disease that causes swelling of extremities, the gastrointestinal tract and upper airways. "We are very pleased with the strong results of this study, which demonstrated efficacy with a low-volume dosing regimen, and what it potentially could mean for the global HAE community, if approved," said Shire (Xetra: S7E.DE - news) 's head of research and development, Howard Mayer.

By using Yahoo, you agree that we and our partners may use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more; Yahoo is now part of ‘Oath’ and a member of the Verizon family of companies. As of 15 September 2017, we plan to share some user information within our new family. Learn more